Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Michael Stanglmaier"'
Autor:
Hans-Jochem Kolb, Johanna Tischer, Belinda Pinto Simões, Raymund Buhmann, Horst Lindhofer, Christoph Schmid, Michael Stanglmaier, Christine S. Falk, Iris Bigalke, Ting Yang, Georg Ledderose
Publikováno v:
Stem Cell Transplantation: Biology, Processing, and Therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e7b4e03e3aee69cff14f42d03fdc734a
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/100222
https://opus.bibliothek.uni-augsburg.de/opus4/frontdoor/index/index/docId/100222
Autor:
Paul G. Schlegel, Raymund Buhmann, Jürgen Hess, Beate Winkler, Wilhelm Woessmann, Meinolf Siepermann, Arndt Borkhardt, Horst Lindhofer, Michael Stanglmaier, Roland Meisel, Friedhelm R. Schuster
Publikováno v:
British Journal of Haematology. 169:90-102
Summary Children with B cell malignancies refractory to standard therapy are known to have a poor prognosis and very limited treatment options. Here, we report on the treatment and follow-up of ten patients diagnosed with relapsed or refractory matur
Autor:
Buhmann, Raymund1,2 raymund.buhmann@med.uni-muenchen.de, Michael, Stanglmaier3, Juergen, Hess3, Horst, Lindhofer3,4, Peschel, Christian5, Kolb, Hans-Jochem2
Publikováno v:
Journal of Translational Medicine. 2013, Vol. 11 Issue 1, p1-9. 9p. 2 Diagrams, 3 Charts.
Autor:
Petra Schröder, Peter Ruf, Michael Stanglmaier, Horst Lindhofer, Annette Bodenhausen, Margot Faltin
Publikováno v:
International Journal of Cancer. 123:1181-1189
Trifunctional bispecific antibodies can efficiently mediate tumor cell killing by redirecting T cells and immune accessory cells to the tumor cell. Here, we describe the new trifunctional antibody, Bi20 (FBTA05, anti-CD20 x anti-CD3), that connects B
Autor:
Raymund Buhmann, Peter Ruf, Michael Jäger, Horst Lindhofer, Michael Stanglmaier, Juergen Hess, Daniel Klunker
Publikováno v:
Handbook of Therapeutic Antibodies
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8a7598a9fdefb2382e6b41f09175d991
https://doi.org/10.1002/9783527682423.ch51
https://doi.org/10.1002/9783527682423.ch51
Autor:
Gabriele Multhoff, Michael Stanglmaier
Publikováno v:
Tumor Immunology and Immunotherapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::21c09e668031766af6ab0be52bb90797
https://doi.org/10.1093/med/9780199676866.003.0025
https://doi.org/10.1093/med/9780199676866.003.0025
Publikováno v:
Annals of hematology. 83(10)
The monoclonal antibodies (MoAbs) alemtuzumab (anti-CD52) and rituximab (anti-CD20) produce objective clinical responses in patients with chronic lymphocytic leukemia (CLL). However, their mechanisms of action are not fully understood. Therefore, we
Autor:
Eva M. Schier, Bernd Hubner, Silke Reiffert, Matt Dunn, Benno Rattel, Stefan Zahn, Kurt Lobenwein, Mark G. Wing, Corinna Löhning, Michael Tesar, Zoltan Nagy, Titus Kretzschmar, Michael Stanglmaier, Steve Anderson, Angelika Zahradnik, Sigmar Leyer, Elisabeth Thomassen-Wolf, Christoph Brunner, Robert Rauchenberger, Michael Hallek
Publikováno v:
Nature medicine. 8(8)
The Human Combinatorial Antibody Library (HuCAL) was screened for antibodies specific to human leukocyte antigen-DR (HLA-DR) that induce programmed death of lymphoma/leukemia cells expressing the target antigen. The active Fab fragments were affinity
Publikováno v:
Gene. 168(2)
Sequences of the open reading frames encoding adenovirus type 4 (Ad4) DNA polymerase and the terminal protein precursor were determined. Sequence comparisons with the corresponding genes and proteins from Ad2 and Ad5 show high overall identity, but s